Drug
Chf6333
Chf6333: highest development phase Phase 1/2, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| CHF6333 NCT06166056 | Phase 1/2 | Bronchiectasis |
Latest
No recent events.
Follow Chf6333 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.